BamSEC and AlphaSense Join Forces
Learn More

Puma Biotechnology Inc

NASDAQ: PBYI    
Share price (1/3/25): $2.95    
Market cap (1/3/25): $145 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 1 page Sixth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan
12/34/56
EX-10.1
from 10-Q 6 pages Seventh Amendment to Note Purchase Agreement and Third Amendment to Disclosure Letter
12/34/56
EX-10.2
from 10-Q 5 pages Sixth Amendment to Note Purchase Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Limited Waiver and Fifth Amendment to Note Purchase Agreement
12/34/56
EX-10.17E
from 10-K 8 pages Fourth Amendment to Note Purchase Agreement and Second Amendment to Disclosure Letter
12/34/56
EX-10.17C
from 10-K 6 pages Second Amendment to Note Purchase Agreement
12/34/56
EX-10.1
from 8-K 26 pages Puma Biotechnology, Inc. Securities Purchase Agreement
12/34/56
EX-10.2
from 10-Q 41 pages Exclusive License Agreement
12/34/56
EX-10.1
from 10-Q 9 pages Third Amendment to Note Purchase Agreement
12/34/56
EX-10.1
from S-3 34 pages Puma Biotechnology, Inc. Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Puma Biotechnology, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.18B
from 10-K 6 pages First Amendment to Note Documents
12/34/56
EX-10.1
from 10-Q 140 pages Note Purchase Agreement Dated as of July 23, 2021 Among Puma Biotechnology, Inc. as the Issuer, Certain Subsidiaries of the Issuer, as the Guarantors, Athyrium Opportunities IV Co-Invest 1 LP as the Administrative Agent and the Purchasers From Time to Time Party Hereto
12/34/56
EX-10.1
from 8-K 2 pages Fifth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan
12/34/56
EX-10.3
from 10-Q 15 pages Amendment N°3 to License Agreement
12/34/56
EX-10.2
from 10-Q 23 pages Termination Agreement
12/34/56
EX-10.19
from 10-K 7 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. February 13, 2020 Jeff J. Ludwig via E-Mail Re:employment Offer Letter Dear Jeff
12/34/56
EX-10.1(D)
from 10-K 5 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. October 29, 2020 Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150 Los Angeles, Ca 90024 Attention: Alan Auerbach Re:amendment No. 2 to the License Agreement Between Pfizer Inc. and Puma Biotechnology, Inc. Dear Mr. Auerbach
12/34/56
EX-10.2
from 10-Q 4 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. June 8, 2020 Mr. Alan H. Auerbach (Via Electronic Mail) Chief Executive Officer, President and Chairman of the Board Puma Biotechnology Inc. 10940 Wilshire Blvd, Suite 600 Los Angeles, Ca 90024 Re: Nerlynx® (Neratinib) Milestone Achievement Dear Alan,
12/34/56
EX-10.3
from 10-Q 3 pages Puma Biotechnology, Inc. Non-Employee Director Compensation Program
12/34/56